Composition containing Bifidobacterium for alleviating, preventing or treating rheumatoid arthritis

Abstract

Provided is a composition containing Bifidobacterium for alleviating, preventing or treating rheumatoid arthritis. The Bifidobacterium bifidum ATT newly isolated according to the present invention is useful as a rheumatoid arthritis medicine or a probiotic material for alleviating rheumatoid arthritis owing to potent efficacy in treating rheumatoid arthritis.

Claims

1. A method of treating or alleviating rheumatoid arthritis comprising administering a composition comprising an effective amount of culture solution or dried powder of Bifidobacterium bifidum ATT (accession number: KCTC13474BP) to a subject in need thereof.

2. The method of claim 1, wherein the composition is a food composition for alleviating rheumatoid arthritis.

3. The method of claim 1, wherein the composition is a pharmaceutical composition for treating rheumatoid arthritis.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) The above and other objects, features and other advantages of the present invention will be more clearly understood from the following detailed description taken in conjunction with the accompanying drawings, in which:

(2) FIG. 1 shows an analysis result of intestinal microbial flora distributions on normal subjects and Korean rheumatoid arthritis patients (Normal: normal subject, RA: rheumatoid arthritis patient);

(3) FIG. 2 shows an analysis result of intestinal microbial flora distributions depending on stage and treatment method on normal subjects and Korean rheumatoid arthritis patients (Normal: normal group, Preclinical: group with no rheumatoid arthritis symptom, Drug Naive: group diagnosed with rheumatoid arthritis, DMARD: group treated with an antirheumatic drug (methotrexate (MTX)), BL: group treated with a primary biologic (TNF inhibitor), BS: group treated with a secondary biologic (IL-6R mAb, CTLA4-Ig));

(4) FIG. 3 shows an analysis result of adhesion to the intestine of the Bifidobacterium bifidum ATT found by the present invention;

(5) FIG. 4 shows an analysis result of a control effect of Bifidobacterium bifidum ATT on rheumatoid arthritis [(A) comparison in rheumatoid arthritis score (p<0.001***, p<0.01**, p<0.05*), (B) comparison in rheumatoid arthritis incidence (p<0.001***, p<0.01**, p<0.05*)];

(6) FIG. 5 shows an analysis result of inhibition on IL-8 secretion of Bifidobacterium bifidum ATT in human colon cancer cell line HT-29 [(A) IL-1 treatment group, (B) TNF treatment group, (C) LPS treatment group]; and

(7) FIG. 6 shows an analysis result of IgG antibody expression in the rheumatoid arthritis-induced mouse serum [(A): IgG, (B): IgG2a, (C): IgG specific to rheumatoid arthritis antibody (type ii collagen; Cii) (Cii-specific lgG), (D): IgG2a specific to rheumatoid arthritis antibody (type ii collagen; Cii) (Cii-specific IgG2a); Vehicle: group to which Bifidobacterium bifidum ATT is not administered, Bifidobacterium biffidum ATT: group to which Bifidobacterium bifidum ATT is administered; p<0.05*).

DETAILED DESCRIPTION OF THE INVENTION

(8) Reference will now be made in detail to the preferred embodiments of the present invention, examples of which are illustrated in the accompanying drawings. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts.

(9) The present invention provides Bifidobacterium bifidum ATT (accession number: KCTC13474BP) effective for preventing or treating rheumatoid arthritis. The present invention proved that Bifidobacterium bifidum ATT is capable of being highly adhered to intestinal cells, slowing down the onset of rheumatoid arthritis and significantly reducing the incidence of rheumatoid arthritis.

(10) Accordingly, the present invention provides a food composition for alleviating rheumatoid arthritis which contains a culture solution of Bifidobacterium bifidum ATT (accession number: KCTC13474BP) or a dried powder thereof. Regarding the food composition for alleviating rheumatoid arthritis according to the present invention, the Bifidobacterium bifidum ATT is preferably present in an amount of 0.00001 to 50% by weight with respect to the weight of the food composition for alleviating rheumatoid arthritis. When the Bifidobacterium bifidum ATT is present in an amount of less than 0.00001% by weight, effects thereof are unsatisfactory, and when the Bifidobacterium bifidum ATT is present in an amount higher than 50% by weight, the effects thereof are poor, compared to the amount of Bifidobacterium bifidum ATT used, thus making it less economical.

(11) For example, the food composition for alleviating rheumatoid arthritis according to the present invention is selected from the group consisting of meat, cereal, caffeinated beverages, regular beverages, chocolate, bread, snacks, confectionery, candy, pizza, jelly, noodles, gums, dairy products, ice cream, alcoholic beverages, alcoholic drinks, vitamin complexes and other health supplement foods, but the present invention is not limited thereto.

(12) The present invention provides a pharmaceutical composition for preventing or treating rheumatoid arthritis which contains a culture solution of Bifidobacterium bifidum ATT (accession number: KCTC13474BP) or a dried powder thereof.

(13) Meanwhile, the pharmaceutical composition for preventing or treating rheumatoid arthritis according to the present invention may further include a pharmaceutically acceptable carrier, diluent or excipient, in addition to the active ingredient. Examples of suitable carriers, excipients or diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, amorphous cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and a combination thereof. In addition, the drug, which is the pharmaceutical composition for preventing or treating rheumatoid arthritis according to the present invention, may further include one or more selected from fillers, anti-coagulants, lubricants, wetting agents, perfumes, emulsifiers and preservatives.

(14) Meanwhile, the pharmaceutical composition for preventing or treating rheumatoid arthritis according to the present invention is preferably formulated depending on application method. In particular, the pharmaceutical composition is preferably formulated by selecting a method well-known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to mammals. Specifically, examples of the formulation may include any one selected from plasters, granules, lotions, liniments, lemonades, aromatic waters, powders, syrups, ophthalmic ointments, liquids and solutions, aerosols, extracts, elixirs, ointments, fluidextracts, emulsions, suspensions, decoctions, infusions, ophthalmic solutions, tablets, suppositories, injections, spirits, cataplasma, capsules, creams, troches, tinctures, pastes, pills, and soft or hard gelatin capsules.

(15) Meanwhile, the dose of the pharmaceutical composition for preventing or treating rheumatoid arthritis according to the present invention is preferably determined in consideration of method of administration, age, gender and weight of patients and severity of diseases. For example, the pharmaceutical composition for preventing or treating rheumatoid arthritis according to the present invention can be administered at least once in a daily dose of 0.00001 to 100 mg/kg (body weight). However, the dose is provided as an example and can be changed by the physician's prescription depending on the conditions of a patient.

(16) Hereinafter, the present invention will be described in more detail with reference to the following Example or Test Example. The scope of the present invention is not limited to the following Example or Test Example, and includes modifications of the technical concept equivalent thereto.

Example 1: Confirmation of Effects of Bifidobacterium bifidum ATT on Rheumatoid Arthritis

(17) (1) Confirmation of Intestinal Microbial Flora Distributions of Korean Rheumatoid Arthritis Patients

(18) In order to analyze the intestinal microbial flora composition of rheumatoid arthritis patients, fecal samples were collected from 3 normal subjects and 79 Korean rheumatoid arthritis patients, and stored at 80 C. Then, in order to conduct next generation sequencing on the fecal samples, bacterial genomic DNAs were isolated from the fecal samples and 16S rRNA genes specific to microorganisms were amplified to produce a library. The 16S rRNA genes of the library were decoded using Misep available from Illumina Inc. The decoded sequences were subjected to bio-informatic analysis using QllME1.9.1 (open-source bioinformatic pipeline) (FIG. 1). FIG. 1 shows an analysis result of intestinal microbial flora distributions on normal subjects and Korean rheumatoid arthritis patients (Normal: normal subject, RA: rheumatoid arthritis patient). The analysis result of intestinal microbial flora showed that the rheumatoid arthritis patient group exhibited a decrease in Bifidobacterium genus compared to the normal subjects (p=0.03).

(19) (2) Confirmation of Intestinal Microbial Flora Distribution Depending on Stages and Treatment Methods of Korean Rheumatoid Arthritis Patients

(20) In order to analyze the intestinal microbial flora composition in rheumatoid arthritis patients, 3 normal subjects (Normal group) and 79 Korean rheumatoid arthritis patients were classified, based on stages and treatment methods, into five groups in total, that is, a group with no rheumatoid arthritis symptom (Preclinical rheumatoid arthritis), a group diagnosed with rheumatoid arthritis (Drug Naive Rheumatoid Arthritis), a group treated with an antirheumatic drug (Conventional DMARD; methotrexate (MTX)), a group treated with a primary biologic (Biologic, BL; TNF inhibitor) and a group treated with a secondary biologic (2nd Biologic, BS; IL-6R mAb, CTLA4-Ig). The group with no rheumatoid arthritis symptom (Preclinical Rheumatoid Arthritis) means a group of patients who show an increase in RA (rheumatoid arthritis) index, but have no rheumatoid arthritis symptoms, and the group diagnosed with rheumatoid arthritis (Drug Naive Rheumatoid Arthritis) means a group of patients who are diagnosed with rheumatoid arthritis, but do not take any drug.

(21) Then, fecal samples were collected from the subjects' fecal samples and stored at 80 C. Then, in order to conduct next generation sequencing on the fecal samples, bacterial genomic DNAs were isolated from the fecal samples and 16S rRNA genes specific to microorganisms were amplified to produce a library. The 16S rRNA genes of the library were decoded using Misep available from Illumina Inc. The decoded sequences were subjected to bio-informatic analysis using QllME1.9.1 (open-source bioinformatic pipeline) (FIG. 2). FIG. 2 shows an analysis result of intestinal microbial flora distribution depending on stage and treatment method on normal subjects and Korean rheumatoid arthritis patients (Normal: a normal group, Preclinical: a group with no rheumatoid arthritis symptom, Drug Naive: a group diagnosed with rheumatoid arthritis, DMARD: a group treated with an antirheumatic drug (methotrexate (MTX)), BL: a group treated with a primary biologic (TNF inhibitor), BS: a group treated with a secondary biologic (IL-6R mAb, CTLA4-Ig)).

(22) As a result of analysis of the intestinal microbial flora distributions in the normal group and five drug administration groups, it can be seen that, as reaction to the rheumatoid arthritis drug decreases, compared to the normal group, Bifidobacterium spp. is decreased. The patient group, to which a biologic is firstly administered, does not react to DMARD, which is a conventional drug and thus shows lower Bifidobacterium distribution than the DMARD group and much lower Bifidobacterium distribution than the normal subject (p-value<0.01). The patient group, to which a biologic is secondarily (or tertiary) administered, does not react to the primary biologic and thus shows the lowest Bifidobacterium distribution among all the groups, and shows a significant decrease in Bifidobacterium distribution as compared to the normal subject (p<0.01).

(23) (3) Isolation of Bifidobacterium Spp.

(24) The present inventors chose a variety of Bifidobacterium genera from human feces, chose Bifidobacterium bifidum ATT effective for treating rheumatoid arthritis through preliminary tests, deposited at the Korea Research Institute of Bioscience and Biotechnology on Jan. 30, 2018, and then received an accession number of KCTC13474BP.

Test Example 1: Confirmation of Adhesion to Intestine of Bifidobacterium bifidum ATT

(25) In order to ascertain the ability of Bifidobacterium bifidum ATT to be adhered to the intestine found by the present invention, the human colonic epithelial cell line, Caco-2 was seeded at a concentration of 110.sup.5 cells/well on a 24-well plate and cultured for 14 days. Then, the cells were treated with 110.sup.8 CFU of Bifidobacterium bifidum ATT having been cultured in MRS liquid medium for 18 hours and then cultured for 1 hour. After culturing for one hour, a beneficial bacteria suspension was injected into the cells, the cells were washed with PBS three times to remove the remaining cells and were harvested with trypsin EDTA, and the genomic DNAs were extracted. A standard curve was drawn using qPCR with a primer specific to the Bifidobacterium bifidum ATT, and the amount of Bifidobacterium bifidum ATT contained in the genomic DNAs extracted in the sample was weighed to check adhesion capability (FIG. 3). FIG. 3 shows an analysis result of adhesion to the intestine of the Bifidobacterium bifidum ATT found by the present invention. According to Candela's method (Candela M, Seibold G, Vitali B, Lachenmaier S, Eikmanns B J and Brigidi P. 2005. Research in Microbiology. 156: 887-895.), the adhesion of bacteria is strong when the number of bacteria adhered to 100 Caco-2 cells is more than 40. In consideration of this standard, the Bifidobacterium bifidum ATT exhibits considerably excellent adhesion to intestinal cells.

Test Example 2: Confirmation of Inhibitory Effect of Bifidobacterium bifidum ATT on Secretion of IL-8 in Human Colon Cancer Cell Line

(26) In order to confirm whether Bifidobacterium bifidum ATT inhibits secretion of IL-8 in the human colon cancer cell line, Bifidobacterium bifidum ATT was orally administered at a concentration of 100 mg/kg to rheumatoid arthritis subjects daily for one week after the onset of rheumatoid arthritis. Rheumatoid arthritis started to develop 21 days after disease induction, and the group, to which Bifidobacterium bifidum ATT was administered, started to develop the disease 30 days after disease induction, but showed significant inhibition of the disease, compared to the rheumatoid arthritis control group. The incidence of rheumatoid arthritis was significantly inhibited in the group to which Bifidobacterium bifidum ATT was administered (FIG. 4). FIG. 4 shows an analysis result of a control effect of Bifidobacterium bifidum ATT on rheumatoid arthritis [(A) comparison in rheumatoid arthritis score (p<0.001***, p<0.01**, p<0.05*), (B) comparison in rheumatoid arthritis incidence (p<0.001***, p<0.01**, p<0.05*)].

Test Example 3: Confirmation of Inhibitory Effect of Bifidobacterium bifidum ATT on Development of Rheumatoid Arthritis

(27) In order to weigh the amount of inflammatory factor IL-8 (interleukin 8) secreted in the human colon cancer cell (HT-29 cell) line, IL-1, TNF- and LPS as stimulus sources, and Bifidobacterium bifidum ATT (110.sup.8 CFU/ml) were applied to the HT-29 cell monolayer and cultured for 6 hours. To assay IL-8 secreted from the cells, the supernatant was collected and analyzed using a Human IL-8 ELISA Set (BD, San Diego, USA) (FIG. 5). FIG. 5 shows an analysis result of inhibition on IL-8 secretion of Bifidobacterium bifidum ATT in human colon cancer cell line HT-29 [(A) IL-1 treatment group, (B) TNF treatment group, (C) LPS treatment group]. When Bifidobacterium bifidum ATT was treated in combination with three stimulus sources (IL-1, TNF-, LPS), IL-8 expression caused by the stimulus sources was similar to that of the non-treatment group and was significantly decreased, compared to the group treated with one kind of stimulus source (p<0.05).

Test Example 4: Analysis of IgG Antibody Expression in Rheumatoid Arthritis Animal Serum

(28) In order to analyze expression of IgG antibody in the mouse serum, mouse subjects of Bifidobacterium bifidum ATT non-treatment (Vehicle) and treatment groups (Bifidobacterium bifidum ATT) 63 days after induction of rheumatoid arthritis were subjected to orbital blood collection and the serum was isolated from the blood. IgG, IgG2a, IgG specific to the rheumatoid arthritis antibody (type ii collagen; Cii) (Cii-specific lgG), and IgG2a specific to the rheumatoid arthritis antibody (Cii-specific IgG2a) were measured from the isolated serum (FIG. 6). FIG. 6 shows an analysis result of IgG antibody expression in the rheumatoid arthritis-induced mouse serum [(A): IgG, (B): IgG2a, (C): IgG specific to the rheumatoid arthritis antibody (type ii collagen; Cii) (Cii-specific lgG), (D): IgG2a specific to the rheumatoid arthritis antibody (type ii collagen; Cii) (Cii-specific IgG2a); Vehicle: group to which Bifidobacterium bifidum ATT is not administered, Bifidobacterium bifidum ATT: group to which Bifidobacterium bifidum ATT is administered; p<0.05*]. The group, to which Bifidobacterium bifidum ATT was administered, exhibited inhibition on arthritis activity and antibody activity through a rheumatoid arthritis antigen-specific probiotic composite (p<0.05*).

(29) As is apparent from the above description, the Bifidobacterium bifidum ATT newly isolated according to the present invention is useful as a rheumatoid arthritis medicine or a probiotic material for alleviating rheumatoid arthritis owing to potent efficacy in treating rheumatoid arthritis.

(30) Although the preferred embodiments of the present invention have been disclosed for illustrative purposes, those skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as disclosed in the accompanying claims.

ACCESSION NUMBER

(31) Deposition organization: Korea Research Institute of Bioscience and Biotechnology

(32) Accession number: KCTC13474BP

(33) Deposition date: 20180130